

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BeiGene, Ltd.**

**百濟神州有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 06160)**

## **VOLUNTARY ANNOUNCEMENT – UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS**

### **UPDATE REGARDING THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (NRDL)**

As previously announced, the following medicines and/or new indications of BeiGene, Ltd. (the “**Company**”) have been included in the updated National Reimbursement Drug List (NRDL) at the NRDL payment standard set forth below, effective January 1, 2022. For innovative medicines, such as our medicines, the NRDL payment standard is determined through negotiation between the marketing authorization holder (MAH) and the National Healthcare Security Administration (NHSA), and applied nationwide for the reimbursement of such medicines through China’s public medical insurance system.

- Tislelizumab is included in the NRDL in all five of its approved indications – three new indications included since January 2022 and two indications included since March 2021 (NRDL payment standard: RMB1,450 per 100mg vial):
  - For use in combination with pemetrexed and platinum chemotherapy as a first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), with EGFR genomic tumor aberrations negative and ALK genomic tumor negative (approved in June 2021 and included in the NRDL since January 2022);
  - For the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with at least one systemic therapy (conditionally approved in June 2021 and included in the NRDL since January 2022);
  - For use in combination with paclitaxel and carboplatin as a first-line treatment in patients with unresectable, locally advanced or metastatic squamous NSCLC (approved in January 2021 and included in the NRDL since January 2022);

- For the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy (conditionally approved in April 2020 and included in the NRDL since March 2021); and
- For the treatment of patients with classical Hodgkin's lymphoma (cHL) who have received at least two prior therapies (conditionally approved in December 2019 and included in the NRDL since March 2021).
- BRUKINSA® is included in the NRDL in all three of its approved indications – one new indication since January 2022 and two indications since March 2021 (NRDL payment standard: RMB85 per 80mg capsule (64 capsules per bottle)):
  - For the treatment of adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy (conditionally approved in June 2021 and included in the NRDL since January 2022);
  - For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy (conditionally approved in June 2020 and included in the NRDL since January 2022); and
  - For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy (conditionally approved in June 2020 and included in the NRDL since March 2021).
- Pamiparib is included in the NRDL since January 2022 in its approved indication (NRDL payment standard: RMB53.60 per 20mg capsule (60 capsules per bottle)):
  - For the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy (conditionally approved in May 2021 and included in the NRDL since January 2022).

By order of the Board  
**BeiGene, Ltd.**  
**Mr. John V. Oyler**  
*Chairman*

Hong Kong, January 10, 2022

*As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Corazon (Corsee) D. Sanders, Mr. Jing-Shyh (Sam) Su and Mr. Qingqing Yi as Independent Non-executive Directors.*